Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Benzinga · 1d ago
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.